Who are SCH-58235's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tryvio, SPARSENTAN, Opsumit, Letairis, Tracleer, "Nefecon®","Ambrisentan".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sch-58235.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

SCH-58235 — Competitive Intelligence Brief

SCH-58235 (SCH-58235) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 3 Endothelin receptor antagonist Endothelin receptor (ETA/ETB) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

SCH-58235 (SCH-58235) — National Heart, Lung, and Blood Institute (NHLBI). SCH-58235 is a selective endothelin receptor antagonist that blocks endothelin-1 signaling to reduce pulmonary vascular resistance and improve hemodynamics in pulmonary hypertension.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SCH-58235 TARGET	SCH-58235	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
Tryvio	APROCITENTAN	Idorsia	marketed	Endothelin Receptor Antagonist [EPC]		2025-01-01
SPARSENTAN	SPARSENTAN		marketed	Endothelin Receptor Antagonist [EPC]		2023-01-01
Opsumit	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01
Tracleer	BOSENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)

Recent regulatory actions (last 90 days)

2026-03-03 — Tracleer · FDA · approved · US · AstraZeneca

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-15 — Tracleer · 8309126 · Formulation · US
2027-12-28 — Tracleer · 7959945 · Formulation · US

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SCH-58235 — Competitive Intelligence Brief. https://druglandscape.com/ci/sch-58235. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab